Please ensure Javascript is enabled for purposes of website accessibility

Why Regeneron Pharmaceuticals Shot 7% Higher on Monday

By Eric Volkman – Oct 5, 2020 at 7:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A famous person received the company's experimental COVID-19 treatment.

What happened

Late last week, Regeneron Pharmaceuticals' (REGN -0.47%) experimental COVID-19 treatment was administered to President Donald Trump. Perhaps it helped; Trump tweeted that he was "feeling really good!" Trump left Walter Reed Medical Center on Monday evening to return to work at the White House.

News that Trump was scheduled to return to the official residence powered Regeneron to a 7%-plus gain on the day. It's worth noting that Trump was also given remdesivir, the repurposed antiviral drug from pharmaceutical industry peer Gilead Sciences (GILD 3.09%); however, that company's stock rose a comparatively light 2.3% on Monday.

Donald Trump at a desk in Walter Reed Medical Center.

Image source: The White House.

So what

Regeneron's REGN-COV2 is a cocktail of two antibodies, which are proteins manufactured by the body's immune system to combat illnesses.

It's been in the news lately because last week, Regeneron published the first results from its phase 1/2/3 clinical trials indicating that the candidate is effective in fighting the disease.

The first 275 patients tracked in the study had mild to moderate forms of the illness, and those administered the cocktail demonstrated notable reductions in viral load. Only two developed side effects, and they were taking placebos.

Now what

While REGN-COV2's published results were very encouraging for shareholders, and its use in Trump's treatment was also a heartening sign, there are still more questions than answers regarding its future. It requires much more clinical testing, so potential regulatory approval and a positive outcome for the company are in no way assured. While it's reasonable for investors to be somewhat optimistic about Regeneron stock, some caution is warranted here.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
$731.65 (-0.47%) $-3.48
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$64.25 (3.09%) $1.93

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.